Slide 1: Corporate presentation April 2016
Corporate presentation April 2016 For personal use only David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Research - Ultrasonic Blood Flow Monitoring1
Slide 2: Who is Compumedics?
Who is Compumedics? For personal use only A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring Diagnosing disorders including Highly sophisticated of blood flow through sleep disorders long-term epilepsy brain research the brai
Slide 3: Revenue Composition at $33.4m
Revenue Composition at $33.4m 30 June 2015 For personal use only By geographic region By product/market Supply Tech. Europe, Items, Service, 16% Brain 9% 8% USA, 34% Blood Flow, Sleep, 21% 28% Asia, 34% Brain Aust, Res, Neuro, 16% 21% 12% Software upgrades 5 to 10% of system sales Compumedics sells
Slide 4: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out For personal use only Sales – schematic only FY16F FY17F FY18F FY19F FY20F Core - Base Core - Sleep/Neuro - Mid Market Neuro - MEG Sleep - eHealth • Step-out - NEURO – BRAIN IMAGING – By signing the new MEG* Agreement with KRISS we can transition from a USD30k sof
Slide 5: Core Business – Premium Focus
Core Business – Premium Focus For personal use only Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics
Slide 6: Core Business – Margin Improved
Core Business – Margin Improved For personal use only 45,000 $k 5,000 40,000 EBITDA 4,000 35,000 3,000 30,000 25,000 Revenues 2,000 20,000 1,000 15,000 - 10,000 -1,000 5,000 - -2,000 2009 2010 2011 2012 2013 2014 2015 AUD/USD Exchange rate 0.9865 1.0324 1.0271 0.8811 0.9188 0.8386 0.7495 2009 2010 2
Slide 7: Core Business – Restored Net Cash Position
Core Business – Restored Net Cash Position For personal use only $m FY09 FY10 FY11 FY12 FY13 FY14 FY15 Cash 0.3 1.8 1.2 1.1 1.3 1.1 2.2 Trade receivables 1.7 9.7 10.2 8.7 8.1 8.6 9.8 Inventories 1.4 5.0 5.7 5.3 5.5 6.1 5.7 Prod. dev’t 8.8 4.2 4.2 4.0 3.5 2.9 2.7 Tax asset 0.3 0.2 0.9 0.0 0.0 0.0 0.0
Slide 8: Core Business – Adding Mid-Tier Range
Core Business – Adding Mid-Tier Range For personal use only Average Product Used for Bought by selling price Hospitals, doctors Grael Sleep and neurology USD17,500 and service providers Hospitals, doctors Somte PSG Sleep USD10,000 and service providers Hospitals, doctors Siesta Sleep and neurology U
Slide 9: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out For personal use only Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Imaging Cloud based sleep Leverage existing Long term epilepsy diagnostic platforms Leverage CURRY TCD technology and Next generation market
Slide 10: Core Business - Growth Drivers
Core Business - Growth Drivers For personal use only Compumedics/NeuroScan LTEM innovative brain analysis software and high performance amplifiers are unrivalled world class technology We have >20,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedi
Slide 11: USA Clinical Sales Force Expansion
USA – CMP is number 3 Supplier USA Clinical Sales Force Expansion For personal use only More sales representatives = more revenue for both sleep and neurology Past USD4.5m FY2015 to now USD6.4m FY2016 USD10.0m FY2017 USD15.0m 11
Slide 12: China - We are the number Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China For personal use only Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin Beijing 88 2 Liaoning Ningxia 23 Qinhuangdao QingHai 3 HeBei 10 3 Tianjin Dalian China Sales – USD’s 2 3 16 14 HeNan 12 Gan
Slide 13: Step out - Brain Imaging: A$9m sales in FY17
Step out 1 - Brain Imaging: A$9m sales in FY17 For personal use only Opportunity Market & Competition Plan Outcome CMP’s CURRY brain The MEG market is currently H2 FY16 – sign LOI CMP plans to sell analysis software is already estimated at about 35 systems a with KRISS for license and install 2 MEG
Slide 14: Step out – eHealth/cloud: A$4m/a sales already
Step out 2 – eHealth/cloud: A$4m/a sales already For personal use only eHealthMedics Operational systems have Compumedics are Key partners has already been developed for the cloud now approaching being locked in excess based capture, transfer a select group of pursued of $10m of and translation of m
Slide 15: Directors & Executive Team
Directors & Executive Team Key Management For personal use only David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 26yrs NED - Mr. Alan Anderson Mr. David Lawson Leading USA Attorney Chief Financial Officer CMP Tenure : 11 yrs & Company Secretary CMP Tenure 13 yrs Mr. Warwick Freeman Kerry
Slide 16: Investor Summary
Investor Summary Core business continues to grow with lower For personal use only cost base and addition of mid-tier International sales force Compumedics remains expansion, neurology market committed to continuing to opportunity and earnings deliver superior returns to improvement initiatives to sh
Slide 17: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability o
Slide 18: compumedics.com.au
For personal use only 18 compumedics.com.au